Details of the Drug Reposition

General Information of This Drug (ID: DM5VH6U)

Drug Name
Serlopitant   DM5VH6U
Synonyms
VPD-737; UNII-277V92K32B; CHEMBL447955; 860642-69-9; 277V92K32B; 3-((3aR,4R,5S,7aS)-5-((R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(4-fluorophenyl)hexahydro-1H-isoindol-2(3H)-yl)cyclopent-2-enone; Serlopitant [USAN:INN]; VPD 737; Serlopitant (USAN); SCHEMBL3183159; GTPL9280; mk-0594; FLNYCRJBCNNHRH-OIYLJQICSA-N; BDBM50277511; compound 17 (Jiang et al. 2009); DB12973; D09378; 3-[(3aR,4R,5S,7aS)-5-{(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}-4-(4-fluorophenyl)octahydro-1H-isoindol-2-yl]cyclopent-2-en-1-one
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Prurigo nodularis DIS2R4Z0 EC91.0 Phase 3 [1]
------------------------------------------------------------------------------------
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Psoriasis vulgaris DIS6M7AN EA90 Phase 2 [1]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)